| __timestamp | Dyne Therapeutics, Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 14562000000 |
| Thursday, January 1, 2015 | 2028000000 | 16188000000 |
| Friday, January 1, 2016 | 2281000000 | 17183000000 |
| Sunday, January 1, 2017 | 2932000000 | 17632000000 |
| Monday, January 1, 2018 | 24000 | 17617000000 |
| Tuesday, January 1, 2019 | 271000 | 20088000000 |
| Wednesday, January 1, 2020 | 700000 | 20932000000 |
| Friday, January 1, 2021 | 1088000 | 23658000000 |
| Saturday, January 1, 2022 | 3345000 | 28448000000 |
| Sunday, January 1, 2023 | 2461000 | 35765000000 |
| Monday, January 1, 2024 | 44522000000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. Novo Nordisk A/S, a global leader in diabetes care, and Dyne Therapeutics, Inc., a burgeoning biotech firm, present a fascinating contrast. Over the past decade, Novo Nordisk has consistently demonstrated robust financial performance, with its cost of revenue peaking at approximately $35.8 billion in 2023, reflecting a steady growth of around 145% since 2014. In contrast, Dyne Therapeutics, a relatively new player, shows a more volatile trajectory. After a significant spike in 2017, its cost of revenue plummeted to a mere $24,000 in 2018, before gradually recovering to $2.5 million in 2023. This disparity highlights the challenges and opportunities faced by established giants and emerging innovators in the pharmaceutical sector.
Cost of Revenue: Key Insights for Novo Nordisk A/S and GSK plc
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Novo Nordisk A/S vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Novo Nordisk A/S vs Alkermes plc: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs ACADIA Pharmaceuticals Inc.
Novo Nordisk A/S vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amgen Inc. and Dyne Therapeutics, Inc.
United Therapeutics Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Xenon Pharmaceuticals Inc. vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down MorphoSys AG and Dyne Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Galapagos NV vs Dyne Therapeutics, Inc.